Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation

Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary macroadenoma who underwent transsphenoidal surgery....

Descripción completa

Detalles Bibliográficos
Autores principales: Mallea-Gil, Maria Susana, Bernabeu, Ignacio, Spiraquis, Adriana, Avangina, Alejandra, Loidi, Lourdes, Ballarino, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763006/
https://www.ncbi.nlm.nih.gov/pubmed/26977326
http://dx.doi.org/10.1155/2016/2087102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763006/
https://www.ncbi.nlm.nih.gov/pubmed/26977326
http://dx.doi.org/10.1155/2016/2087102

Ejemplares similares